APA (7th ed.) Citation

B, H., S, K., JS, J., M, A., J, W., D, Z., . . . Y, W. (2023). Mesalamine and cholestyramine for immune checkpoint inhibitor-mediated diarrhea and colitis. Journal of cancer research and clinical oncology, 149(7), 3637. https://doi.org/10.1007/s00432-022-04116-9

Chicago Style (17th ed.) Citation

B, Hollander, et al. "Mesalamine and Cholestyramine for Immune Checkpoint Inhibitor-mediated Diarrhea and Colitis." Journal of Cancer Research and Clinical Oncology 149, no. 7 (2023): 3637. https://doi.org/10.1007/s00432-022-04116-9.

MLA (9th ed.) Citation

B, Hollander, et al. "Mesalamine and Cholestyramine for Immune Checkpoint Inhibitor-mediated Diarrhea and Colitis." Journal of Cancer Research and Clinical Oncology, vol. 149, no. 7, 2023, p. 3637, https://doi.org/10.1007/s00432-022-04116-9.